The publishing firm Wiley says it is investigating a pivotal paper about a controversial public health tool after Retraction Watch reported on a robust critique of the article which highlighted a number of potentially serious flaws with the research.
We’re talking about the Morisky Medication Adherence Scale (MMAS), whose developer, Donald Morisky, has been hitting researchers with hefty licensing fees — or demands to retract — for nearly two decades.
One of the key papers supporting the validity of the MMAS-8 (the second iteration of the MMAS) was a 2008 article by Morisky and colleagues in the Journal of Clinical Hypertension.
The Lancet has retracted a decade-old case report by a group from Japan after concluding that the authors misrepresented the originality of the work.
The paper was a case report, titled “Hidden Harm,” by a team at Nihon University School of Medicine in Tokyo. The authors described a 46-year-old woman with a history of self-harming behaviors they ultimately attributed to a previously undetected neuroendocrine tumor called a pheochromocytoma.
According to the retraction notice, however, the tumor wasn’t the only thing about the paper that was hidden. The authors also misled the Lancet when they said they hadn’t published about the case when they submitted their writeup about the case — a fact unknown to the journal until this summer:
A company that had offered payment for citations of articles in various journals has ended the practice, and fired the staffer it said was responsible, following reporting by Retraction Watch.
On August 31, we reported that Innoscience Innoscience Research, in Kuala Lumpur, Malaysia, was offering $6 per citation of papers in five different journals, and up to five cites, or $30, per paper, or $150 in total across all five journals. Since then, two journals have distanced themselvesfrom the scheme.
A second journal has said it was unaware of a cash for citations scheme that named it as a participant, following our reporting in August.
The Journal of Clinical and Translational Research (JCTR) was one of five journals listed by Innoscience Research that Innoscience would pay $6 per citation to its work, as we reported on August 31. On October 9, another of those journals said it “will not entertain cash requests from the individuals who claim to have cited our articles, nor shall we pay up.”
A paper claiming that myocarditis cases spiked after teenagers began receiving COVID-19 vaccines has earned a “temporary removal” — without any explanation from the publisher.
It was co-authored by Jessica Rose and Peter McCullough, whose affiliations are listed as the Public Health Policy Initiative at the Institute of Pure and Applied Knowledge — a group that has been critical of vaccines and of the response to COVID-19 and has funded one study that was retracted earlier this year — and Texas A&M’s Baylor Dallas campus. [See update at the end of the post.]
Dove, a publisher owned by Taylor & Francis, has retracted a paper published last year after a Retraction Watch reader pointed out that the authors’ statements on ethical approval made no sense.
Thanks to a publisher’s error, a group of infectious disease researchers has experienced a double negative for their 2020 article on tick-borne illness in South Africa.
A virology journal has retracted and replaced a 2021 article on mosquito-borne infections in Africa after one of the authors identified errors in the publication — an episode that has prompted a change in practice at the journal to avoid similar issues in the future.
The article, “Mosquito-borne arboviruses in Uganda: history, transmission and burden,” was written by a group in the United Kingdom and Uganda and appeared in the Journal of General Virology last June.